Tags

Type your tag names separated by a space and hit enter

FDA should tighten post-marketing surveillance of prescription drugs, says Institute of Medicine.
BMJ. 2012 May 01; 344:e3104.BMJ

Authors

No affiliation info available

Pub Type(s)

News

Language

eng

PubMed ID

22549070

Citation

Roehr, Bob. "FDA Should Tighten Post-marketing Surveillance of Prescription Drugs, Says Institute of Medicine." BMJ (Clinical Research Ed.), vol. 344, 2012, pp. e3104.
Roehr B. FDA should tighten post-marketing surveillance of prescription drugs, says Institute of Medicine. BMJ. 2012;344:e3104.
Roehr, B. (2012). FDA should tighten post-marketing surveillance of prescription drugs, says Institute of Medicine. BMJ (Clinical Research Ed.), 344, e3104. https://doi.org/10.1136/bmj.e3104
Roehr B. FDA Should Tighten Post-marketing Surveillance of Prescription Drugs, Says Institute of Medicine. BMJ. 2012 May 1;344:e3104. PubMed PMID: 22549070.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - FDA should tighten post-marketing surveillance of prescription drugs, says Institute of Medicine. A1 - Roehr,Bob, Y1 - 2012/05/01/ PY - 2012/5/3/entrez PY - 2012/5/3/pubmed PY - 2012/6/19/medline SP - e3104 EP - e3104 JF - BMJ (Clinical research ed.) JO - BMJ VL - 344 SN - 1756-1833 UR - https://www.unboundmedicine.com/medline/citation/22549070/FDA_should_tighten_post_marketing_surveillance_of_prescription_drugs_says_Institute_of_Medicine_ L2 - https://www.bmj.com/lookup/pmidlookup?view=long&pmid=22549070 DB - PRIME DP - Unbound Medicine ER -